An R&D company and a research university have joined forces in the quest for new treatments for a number of serious illnesses,such as cancer,rheumatoid arthritis and infectious diseases.MedImmune,the Gaithersburg,Maryland biotech firm that is a subsidiary of pharma titan AstraZeneca,and Baltimore's The Johns Hopkins University signed the five year,6.5 million dollar research agreement on 11 December.*
The broad-scale,long-term partnership calls for both institutions to contribute funding,personnel and materials to the joint efforts and training programs.We believe this significant collaboration with JHU will create a new standard in how academia and inustry can work together,said Dr.Bahija Jallal,executive vice president at MedImmune.Our partnership with this prestigious research university will leverage each organisation's strength;advance research in critical therapeutic areas;and strengthen Maryland's presence as a growing hub in the bioscience industry.*
We are excited about the opportunity to collaborate with MedImmune researchers to accelerate the development of new therapies to treat a variety of serious diseases such as multiple sclerosis;rheumatoid arthritis;chronic obstructive pulmonary disease;and certain types of cancer,said Landon King,executive vice dean of The Johns Hopkins University School of Medicine.We believe that by working together to leverage the strength of each organisation,we can make significant advances.*
MedImmune focuses on the discovery,development and commercialisation of small molecule and biologic prescription medicines,pioneering innovative research and exploring novel pathways across its key therapeutic areas.It is best known for its vaccines FluMist and Synagis(R),which helps prevent respiratory syncytial virus infections in infants.*
AstraZeneca(AZN)
No comments:
Post a Comment